THE EUROPEAN biotech industry is at a critical stage in its cycle, according to the investment manager of the International Biotechnology trust (IBT).
Andy Smith said a number of companies suffered some setbacks in 2006, and needed their new initiatives to come through for them this year. "European biotechnology is on a knife edge as last year we saw some big blow ups in companies in Europe. "Now a number of companies have had some approvals come through but it is still a hard market to call, and it really is a make or break year." Smith, an employee of European and US based venture capitalist firm SV Life Sciences, handles the public investment decisions regarding IBT. He has overseen the trust outperform the NASDAQ Biotech and ...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
